ReviewMolecular biology reports2026
Advances in epigenetic regulation of potassium channels in chronic pain.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain is characterized by persistent neuronal hyperexcitability. However, the mechanisms underlying its long-term maintenance remain incompletely understood. Emerging evidence indicates that epigenetic regulation plays a critical role in shaping ion channel function, particularly potassium channels, which are key determinants of neuronal excitability. In this review, we systematically summarize how epigenetic mechanisms regulate specific potassium channel subtypes across diverse pain conditions and cell types. Unlike prior reviews on epigenetics in pain, this work focuses on the "epigenetic-potassium channel axis," integrating multi-layered regulation with channel dysfunction across pain models. Despite these advances, key knowledge gaps remain, including the lack of selective tools to modulate channel-specific epigenetic changes, limited understanding of interactions between multiple epigenetic layers, and the absence of reliable biomarkers for monitoring epigenetic regulation in vivo. In addition, translational challenges-such as off-target effects, delivery barriers to pain-relevant neural circuits, and long-term safety concerns-must be addressed before clinical application. This review establishes a multi-layered and context-specific regulatory network linking epigenetic modifications to potassium channels dysfunction, providing new insights into chronic pain mechanisms and informing the development of targeted therapeutic strategies.
Indexed as
Identifiers
42228201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.